Viruses

Bio-Techne's RNAscope™ Technology Aids in the Retrospective Tissue Diagnosis of COVID-19 in cases with no previous testing for SARS-CoV-2

Retrieved on: 
Wednesday, August 4, 2021

RNAscope enables detection of RNA transcripts while retaining cellular morphology, allowing researchers to localize SARS-CoV-2 RNA directly in the tissues, including in the hyaline membranes, pneumocytes and macrophages of lung, and epithelial cells of airways.

Key Points: 
  • RNAscope enables detection of RNA transcripts while retaining cellular morphology, allowing researchers to localize SARS-CoV-2 RNA directly in the tissues, including in the hyaline membranes, pneumocytes and macrophages of lung, and epithelial cells of airways.
  • The SARS-CoV-2 ASR will provide researchers and pathologists with a powerful technology for the detection of SARS-CoV-2 in fixed tissues.
  • During the pandemic, RNAscope probes have been an essential tool in elucidating the pathology of this devastating virus in over one hundred COVID-19 publications to date."
  • Bhatnagar J, Gary J, Reagan-Steiner S, Estetter LB, Tong S, et al.

Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans

Retrieved on: 
Tuesday, August 3, 2021

VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Aug. 3, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that Immunologist Yvelise Barrios, MD, PhD, a specialist in Clinical Immunology at Hospital Universitario de Canarias, Tenerife, Spain, has joined BioVaxys as a Scientific Adviser to support development of CoviDTH, the Company's disposable point-of-care diagnostic tool that screens for a T cell response to SARS-CoV-2 in vaccinated patients or those exposed to SARS-CoV-2. Dr. Barrios is a leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behind CoviDTH, as an immuno-diagnostic tool.

Key Points: 
  • Barrios is a leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behind CoviDTH, as an immuno-diagnostic tool.
  • Dr. Barrios received her medical degree at La Laguna University, Tenerife, Spain and conducted her Clinical Immunology Residency at Puerta de Hierro Hospital.
  • [2] A Novel Application of Delayed-Type Hypersensitivity Reaction to Measure Cellular Immune Response in SARS-CoV-2 Exposed Individuals.
  • Also in development is CoviDTH, a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19.

Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans

Retrieved on: 
Tuesday, August 3, 2021

VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Aug. 3, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that Immunologist Yvelise Barrios, MD, PhD, a specialist in Clinical Immunology at Hospital Universitario de Canarias, Tenerife, Spain, has joined BioVaxys as a Scientific Adviser to support development of CoviDTH, the Company's disposable point-of-care diagnostic tool that screens for a T cell response to SARS-CoV-2 in vaccinated patients or those exposed to SARS-CoV-2. Dr. Barrios is a leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behind CoviDTH, as an immuno-diagnostic tool.

Key Points: 
  • Barrios is a leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behind CoviDTH, as an immuno-diagnostic tool.
  • Dr. Barrios received her medical degree at La Laguna University, Tenerife, Spain and conducted her Clinical Immunology Residency at Puerta de Hierro Hospital.
  • [2] A Novel Application of Delayed-Type Hypersensitivity Reaction to Measure Cellular Immune Response in SARS-CoV-2 Exposed Individuals.
  • Also in development is CoviDTH, a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19.

Ondine Biomedical to present SARS-CoV-2 results at the 19th Congress of the European Society of Photobiology

Retrieved on: 
Tuesday, August 3, 2021

Canadian medical device innovator, Ondine Biomedical, will present in vitro and in vivo results from SARS-CoV-2 programs at the European Society of Photobiology (ESP2021) in Salzburg, Austria on 31st August 2021.

Key Points: 
  • Canadian medical device innovator, Ondine Biomedical, will present in vitro and in vivo results from SARS-CoV-2 programs at the European Society of Photobiology (ESP2021) in Salzburg, Austria on 31st August 2021.
  • The nose and upper airway have been identified as ideal breeding grounds and reservoirs for many pathogens including MRSA, Candida auris and SARS-Cov-2.
  • Dr. Nicolas Loebel, Ondine Biomedicals President and Chief Technology Officer, will present the results in the Photomedicine and SARS-CoV-2/ASP-ESP Symposium.
  • Ondine Biomedical Inc. is a Canadian headquartered, medical device company led by Founder and CEO, Carolyn Cross.

Ondine Biomedical to present results on the effects of its upper airways decolonization technology for SARS-CoV-2 eradication at ICPIC 2021

Retrieved on: 
Monday, July 26, 2021

Canadian medical technology innovator, Ondine Biomedical, will be presenting results from a successful in vitro study of its pioneering Steriwave upper airway disinfection technology against SARS-CoV-2 at the International Conference on Prevention and Infection Control (ICPIC) in Geneva, on 15th September 2021.

Key Points: 
  • Canadian medical technology innovator, Ondine Biomedical, will be presenting results from a successful in vitro study of its pioneering Steriwave upper airway disinfection technology against SARS-CoV-2 at the International Conference on Prevention and Infection Control (ICPIC) in Geneva, on 15th September 2021.
  • The presentation will focus on results demonstrating that this patented photodisinfection therapy can rapidly destroy the RNA genome of SARS-CoV-2.
  • The nose and upper airway have been identified as ideal breeding grounds and reservoirs for many threatening pathogens including MRSA, Candida auris, and SARS-Cov-2.
  • Ondines Steriwave photodisinfection therapy can rapidly and painlessly eradicate pathogens in the nose and upper airway, helping to eliminate a leading source of infection and transmissions.

Innovation Pharmaceuticals Announces New In Vitro Data Supporting Brilacidin’s Broad-Spectrum Antiviral Potential Presented at the American Society of Virology’s Annual Meeting

Retrieved on: 
Thursday, July 22, 2021

New antiviral data included Brilacidins inhibition of SARS-CoV-2 in additional cell lines (Caco-2, primary lung fibroblasts), and Brilacidins inhibition of alphavirusesVenezuelan Equine Encephalitis Virus, Eastern Equine Encephalitis Virusand Rift Valley Fever Virus, a bunyavirus.

Key Points: 
  • New antiviral data included Brilacidins inhibition of SARS-CoV-2 in additional cell lines (Caco-2, primary lung fibroblasts), and Brilacidins inhibition of alphavirusesVenezuelan Equine Encephalitis Virus, Eastern Equine Encephalitis Virusand Rift Valley Fever Virus, a bunyavirus.
  • Our scientific team looks forward to exploring Brilacidin further as we investigate the breadth of its antiviral profile.
  • Brilacidin has shown potent and consistent inhibition in vitro against coronaviruses, alphaviruses and bunyaviruses (with laboratory testing against other viruses also underway), supporting Brilacidins potential to be developed as a broad-spectrum antiviral.
  • A peer-reviewed article in Viruses supporting Brilacidins COVID-19 treatment potential can be accessed at the link below.

Imanis Life Sciences Announces Peer-Reviewed Publication of Data on Quantitative Virus Neutralization Assay IMMUNO-COV™

Retrieved on: 
Tuesday, June 22, 2021

The paper, entitled IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2 Neutralizing Antibody Titers, can be downloaded here .

Key Points: 
  • The paper, entitled IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2 Neutralizing Antibody Titers, can be downloaded here .
  • Imanis is committed to supporting global efforts to standardize SARS-CoV-2 antibody neutralization tests, said Rianna Vandergaast, Ph.D., Principal Scientist at Imanis.
  • Imanis Life Sciences is a biotechnology company with an unwavering commitment to the advancement of science.
  • Imanis Life Sciences is located in Rochester, Minnesota.

Meridian’s New Master Mix for LAMP Assays Offers a Practical Solution for POC Molecular Detection of RNA viruses

Retrieved on: 
Wednesday, June 16, 2021

The Lyo-Ready RT-LAMP Mix is formulated for rapid, robust, and sensitive detection of RNA viruses.

Key Points: 
  • The Lyo-Ready RT-LAMP Mix is formulated for rapid, robust, and sensitive detection of RNA viruses.
  • RT-LAMP has been successfully used in the diagnosis of infectious diseases caused by RNA viruses, such as influenza, hepatitis C, West Nile fever, Dengue virus and Ebola virus.
  • The accuracy and relatively simple equipment requirement makes RT-LAMP the perfect technology for use as a practical solution for point-of-care detection of viruses, particularly in non-standard institutions such as airports, rural hospitals or in the home.
  • Meridian is committed to providing innovative solutions to diagnostic manufacturers that simplify and accelerate the development of superior diagnostic assays.

Encyclopedia of Virology, Edition No. 4 (2021) - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 29, 2021

b'The "Encyclopedia of Virology.

Key Points: 
  • b'The "Encyclopedia of Virology.
  • Edition No.
  • 4" book from Elsevier Science and Technology has been added to ResearchAndMarkets.com\'s offering.\nEncyclopedia of Virology, Fourth Edition, builds on the solid foundation laid by the previous editions, expanding its reach with new and timely topics.
  • In five volumes, the work provides comprehensive coverage of the whole virosphere, making this a unique resource.\nContent explores viruses present in the environment and the pathogenic viruses of humans, animals, plants and microorganisms.

Tonix Pharmaceuticals Reports Positive COVID-19 Vaccine Efficacy Results in Non-Human Primates Vaccinated with TNX-1800 and Challenged with Live SARS-CoV-2

Retrieved on: 
Wednesday, March 17, 2021

At Day 41 after the vaccination, animals were challenged with live SARS-CoV-2 through intra-nasal and intra-tracheal routes.

Key Points: 
  • At Day 41 after the vaccination, animals were challenged with live SARS-CoV-2 through intra-nasal and intra-tracheal routes.
  • Todays results are from the second phase of a study in which TNX-1800 vaccinated and control animals were challenged with SARS-CoV-2.
  • Dr. Lederman continued, Take is considered important because it is otherwise difficult and costly to measure the T cell response to a vaccine.
  • STUDY DESIGN: This study of non-human primates compared TNX-1800 (modified horsepox virus encoding CoV-2 spike protein) to TNX-801 (horsepox virus, live vaccine) at two doses.